University of Michigan Spinoff Lycera Begins First Trials Of U-M Developed & Licensed IBD Drug

University of Michigan Spinoff Lycera Begins First Trials Of U-M Developed & Licensed IBD Drug
Lycera Corp., a University of Michigan spinoff biotech firm based on campus at Ann Arbor, has begun a Phase 1 clinical trial of the Inflammatory Bowel Disease (IBD Drug) LYC-30937 in healthy volunteers. Lycera is a biopharmaceutical company focused on developing breakthrough immunomodulatory medicines for treating autoimmune diseases and cancer. The drug candidate LYC-30937 is an oral gut-directed ATPase modulator designed to treat the inflamed intestines of people with Crohn's disease and ulcerative colitis by selectively inducing cell death (apoptosis) in disease-causing immune cells, sparing normal cells. LYC-30937 was discovered and developed by Lycera based on technology licensed from the University of Michigan; the company maintains full worldwide development and commercial rights. The drug's being a targeted oral formulation makes it an attractive potential alternative to current injected drugs. SekhriPThe initiation of a clinical trials program for LYC-30937 marks a major milestone passed for Lycera. "This is our first program to enter the clinic, as well as the first ATPase modulator to commence clinical testing," says Paul Sekhri, President and CEO of Lycera Corp. "Lycera is dedicated to advancing a portfolio of drugs based on breakthrough science that have the potential to offer substantial advances for patient treatment. We are proud of the progress of our lead program, and look forward to further accelerating additiona
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *